Standard BioTools Inc. Intangible Assets, Net (Excluding Goodwill)
Standard BioTools Inc. (LAB) had Intangible Assets, Net (Excluding Goodwill) of $28.06 million as of 2025-03-31, per its 10-Q filed 2025-05-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2025-05-06
- 2025-03-31: Intangible Assets, Net (Excluding Goodwill) $28.06M.
- 2024-12-31: Intangible Assets, Net (Excluding Goodwill) $28.95M.
- 2024-09-30: Intangible Assets, Net (Excluding Goodwill) $23.37M.
- 2024-06-30: Intangible Assets, Net (Excluding Goodwill) $24.08M.
| Period end | Intangible Assets, Net (Excluding Goodwill) | Intangible Assets, Net (Excluding Goodwill) as first filed |
|---|---|---|
| 2025-03-31 | $28.06M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $28.95M 10-Q · filed 2025-05-06 | |
| 2024-09-30 | $23.37M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $24.08M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $24.79M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $1.40M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $4.20M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $7.00M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $9.80M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $12.60M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $15.40M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $18.20M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $24.88M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $27.93M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $30.99M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $34.08M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $37.00M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $40.21M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $42.95M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $45.64M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $48.61M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $46.20M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $49.00M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $51.80M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $54.60M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $57.40M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $60.20M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $63.00M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $65.80M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $68.60M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $71.40M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $74.20M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $77.00M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $79.80M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $82.64M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $85.44M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $88.25M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $91.00M 10-K · filed 2017-03-03 | $91.05M 10-K · filed 2016-02-29 |
| 2015-09-30 | $93.85M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $96.60M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $99.40M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $102.20M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $105.00M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $107.80M 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $110.60M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $0.00 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |